Ana Meliciano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ana Meliciano has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Margarida Serra
BET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2781-901 Oeiras, Portugal; Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Av. da República, 2780-157 Oeiras, Portugal
4 shared publications - Ana Filipa Louro
Advanced Drug Delivery Pharmaceutical Sciences BioPharmaceuticals R&D AstraZeneca Pepparedsleden 1 Mölndal 431 83 Sweden
2 shared publications - Catarina Freitas
BET Instituto de Biologia Experimental e Tecnológica Oeiras Portugal
2 shared publications - Marta H. G. Costa
BET-Instituto de Biologia Experimental e Tecnológica, Apartado 12, Oeiras 2781-901, Portugal; Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Av. da República, Oeiras 2780-157, Portugal
2 shared publications - Paula Marques Alves
BET Instituto de Biologia Experimental e Tecnológica Oeiras Portugal
2 shared publications - Ana Paula Terrasso
BET Instituto de Biologia Experimental e Tecnológica Oeiras Portugal
1 shared publication
Latest Publications
- Open Access
- 3 September 2025
- Published by Wiley in Biotechnology Journal
- Vol. 20 (9) , e70106
Engineering Characterization of Small‐Scale Bioreactors for Large‐Scale hiPSC Production
Human induced pluripotent stem cells (hiPSC) have great potential for cell therapy applications. To meet the global demand for hiPSC‐derived cell therapies, the implementation of scalable technologies, such as stirred‐tank bioreactors (STB), is essential. However, the addition of physical cues, including shear stress, can impact cell viability and proliferation and requires precise tuning. In this work, we used an engineering characterization approach to estimate the impeller power number (0.5) and investigate the mixing and suspension dynamics in the first generation of small‐scale (0.2 L) DASGIP bioreactors (DASGIP‐STB). By keeping constant power input per volume (P/V = 4.6 W/m3) as a scale‐up criteria, we successfully transferred a hiPSC expansion process to a 0.2 L single‐use STB (BioBLU‐STB) and scaled it up to a single‐use 2 L STB (Univessel‐STB) without compromising cell expansion, viability, and metabolism, as well as hiPSC quality attributes, including their pluripotent phenotype and differentiation potential.
- 3 September 2025
- Published by Wiley in Biotechnology Journal
- Vol. 20 (9) , e70106
Open AccessEngineering Characterization of Small‐Scale Bioreactors for Large‐Scale hiPSC Production
Human induced pluripotent stem cells (hiPSC) have great potential for cell therapy applications. To meet the global demand for hiPSC‐derived cell therapies, the implementation of scalable technologies, such as stirred‐tank bioreactors (STB), is essential. However, the addition of physical cues, including shear stress, can impact cell viability and proliferation and requires precise tuning. In this work, we used an engineering characterization approach to estimate the impeller power number (0.5) and investigate the mixing and suspension dynamics in the first generation of small‐scale (0.2 L) DASGIP bioreactors (DASGIP‐STB). By keeping constant power input per volume (P/V = 4.6 W/m3) as a scale‐up criteria, we successfully transferred a hiPSC expansion process to a 0.2 L single‐use STB (BioBLU‐STB) and scaled it up to a single‐use 2 L STB (Univessel‐STB) without compromising cell expansion, viability, and metabolism, as well as hiPSC quality attributes, including their pluripotent phenotype and differentiation potential.
- 22 April 2024
- Published by Elsevier in Trends in Biotechnology
- Vol. 42 (10) , 1305-1322
A roadmap towards manufacturing extracellular vesicles for cardiac repair
- 22 April 2024
- Published by Elsevier in Trends in Biotechnology
- Vol. 42 (10) , 1305-1322
A roadmap towards manufacturing extracellular vesicles for cardiac repair
- Open Access
- 15 March 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (3) , 953
Clinically Expired Platelet Concentrates as a Source of Extracellular Vesicles for Targeted Anti-Cancer Drug Delivery
The short shelf life of platelet concentrates (PC) of up to 5–7 days leads to higher wastage due to expiry. To address this massive financial burden on the healthcare system, alternative applications for expired PC have emerged in recent years. Engineered nanocarriers functionalized with platelet membranes have shown excellent targeting abilities for tumor cells owing to their platelet membrane proteins. Nevertheless, synthetic drug delivery strategies have significant drawbacks that platelet-derived extracellular vesicles (pEV) can overcome. We investigated, for the first time, the use of pEV as a carrier of the anti-breast cancer drug paclitaxel, considering it as an appealing alternative to improve the therapeutic potential of expired PC. The pEV released during PC storage showed a typical EV size distribution profile (100–300 nm) with a cup-shaped morphology. Paclitaxel-loaded pEV showed significant anti-cancer effects in vitro, as demonstrated by their anti-migratory (>30%), anti-angiogenic (>30%), and anti-invasive (>70%) properties in distinct cells found in the breast tumor microenvironment. We provide evidence for a novel application for expired PC by suggesting that the field of tumor treatment research may be broadened by the use of natural carriers.
- 15 March 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (3) , 953
Open AccessClinically Expired Platelet Concentrates as a Source of Extracellular Vesicles for Targeted Anti-Cancer Drug Delivery
The short shelf life of platelet concentrates (PC) of up to 5–7 days leads to higher wastage due to expiry. To address this massive financial burden on the healthcare system, alternative applications for expired PC have emerged in recent years. Engineered nanocarriers functionalized with platelet membranes have shown excellent targeting abilities for tumor cells owing to their platelet membrane proteins. Nevertheless, synthetic drug delivery strategies have significant drawbacks that platelet-derived extracellular vesicles (pEV) can overcome. We investigated, for the first time, the use of pEV as a carrier of the anti-breast cancer drug paclitaxel, considering it as an appealing alternative to improve the therapeutic potential of expired PC. The pEV released during PC storage showed a typical EV size distribution profile (100–300 nm) with a cup-shaped morphology. Paclitaxel-loaded pEV showed significant anti-cancer effects in vitro, as demonstrated by their anti-migratory (>30%), anti-angiogenic (>30%), and anti-invasive (>70%) properties in distinct cells found in the breast tumor microenvironment. We provide evidence for a novel application for expired PC by suggesting that the field of tumor treatment research may be broadened by the use of natural carriers.